Biodexa reports an R&D update including positive results from the phase I trial of MTX110 in patients with diffuse midline glioma

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, shares an R&D update. Positive top-line results from a recent phase 1 trial of MTX110 in diffuse midline glioma (DMG) patients and preclinical data on tolimidone's beta cell proliferation potential are highlighted.

In a Columbia University Irving Medical Center study, DMG patients received MTX110 via convection-enhanced delivery (CED). Safety was paramount, with infusions limited to two sessions. Despite the trial's primary focus on safety, patients showed a median overall survival of 16.5 months, surpassing historical rates.

Detailed trial results will be presented at the 21st International Symposium on Paediatric Neuro-Oncology (ISPNO 2024). Meanwhile, an inconclusive in vitro experiment assessing tolimidone's beta cell proliferation potential prompts further in vivo preclinical studies. Plans for a phase IIa trial in type 1 diabetes patients are underway.

Biodexa Pharmaceuticals PLC is dedicated to developing innovative treatments for diseases with unmet medical needs.